Olema Pharmaceuticals (OLMA) Amortizatization of Intangibles (2021 - 2026)
Olema Pharmaceuticals (OLMA) reported Amortizatization of Intangibles of $301000.0 for Q1 2026, up 4.88% year-over-year from $287000.0 in Q1 2025, and little changed quarter-over-quarter from $301000.0 in Q4 2025.
Olema Pharmaceuticals (OLMA) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 6 years of Amortizatization of Intangibles data on file, last reported at $301000.0 in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $301000.0, up 4.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (up 3.57% YoY), and the FY2025 annual result was $1.2 million, up 2.26% from the prior year.
- Amortizatization of Intangibles steadied at $301000.0 in Q1 2026 per OLMA's latest filing, from $301000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $327000.0 in Q3 2022 and troughed at $287000.0 in Q2 2024.
- A 5-year average of $307352.9 and a median of $301000.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- On a YoY basis, Amortizatization of Intangibles climbed as much as 604.69% in 2022 and fell as far as 77.42% in 2022.
- A 5-year view of Amortizatization of Intangibles shows it stood at $326000.0 in 2022, then slipped by 0.61% to $324000.0 in 2023, then dropped by 11.42% to $287000.0 in 2024, then gained by 4.88% to $301000.0 in 2025, then changed by 0.0% to $301000.0 in 2026.
- Business Quant data shows OLMA's Amortizatization of Intangibles at $301000.0 in Q1 2026, $301000.0 in Q4 2025, and $300000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Olema Pharmaceuticals | 1.01 Bn | 1.01 Bn | - | 301,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 301,000.00 |
| Mar 31, 2026 | 301,000.00 |
| Dec 31, 2025 | 301,000.00 |
| Dec 31, 2025 | 301,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 288,000.00 |
| Jun 30, 2025 | 288,000.00 |
| Mar 31, 2025 | 287,000.00 |
| Mar 31, 2025 | 287,000.00 |
| Dec 31, 2024 | 287,000.00 |
| Dec 31, 2024 | 287,000.00 |
| Sep 30, 2024 | 288,000.00 |
| Sep 30, 2024 | 288,000.00 |
| Jun 30, 2024 | 287,000.00 |
| Jun 30, 2024 | 287,000.00 |
| Mar 31, 2024 | 288,000.00 |
| Mar 31, 2024 | 288,000.00 |
| Dec 31, 2023 | 324,000.00 |
| Dec 31, 2023 | 324,000.00 |